Gotu Kola

Metadata

Approved Indications

Commission E (Germany)

• No monograph issued
• Gotu kola was not evaluated by Commission E, likely because it is not a traditional Central European herb

ESCOP Monograph

• No monograph issued
• ESCOP has not published a monograph on Centella asiatica

EMA/HMPC

• Traditional use: Relief of symptoms of discomfort and heaviness of legs related to minor venous circulatory disturbances
• Traditional use: Aid in healing of minor wounds
• The HMPC noted that clinical studies exist but considered them insufficient in methodological quality for well-established use classification
• Applicable to powdered herbal substance and dry extracts

Agreement/Disagreement Between Bodies

• Significant gap: EMA has issued a monograph, but neither Commission E nor ESCOP has addressed this herb
• This reflects gotu kola’s position as a non-native European herb that entered Western phytotherapy relatively recently from Ayurvedic and Southeast Asian traditions
• The clinical evidence base (particularly for CVI) is arguably stronger than what the regulatory coverage suggests
• In contrast, gotu kola is well-recognized in the Ayurvedic Pharmacopoeia and the WHO Monographs on Selected Medicinal Plants (Volume 1)

Conditions Treated

Primary (Strong Evidence)

• Chronic venous insufficiency (CVI) — heavy legs, ankle edema, varicose veins
• Venous hypertensive microangiopathy — impaired microcirculation in venous disease
• Wound healing — acceleration of granulation and re-epithelialization
• Hypertrophic scars and keloids — reduction of excessive collagen deposition

Secondary (Moderate Evidence)

• Diabetic microangiopathy — improved microcirculation in diabetic patients
• Flight microangiopathy — prevention of ankle edema during long-haul flights
• Burn wound healing (adjunctive)
• Post-surgical scar management

Traditional/Historical (Limited Evidence)

• Cognitive enhancement and memory improvement (Ayurvedic “medhya rasayana” — brain tonic)
• Anxiety and stress reduction
• Skin conditions — psoriasis, scleroderma (case reports)
• Gastric ulcer healing (animal models)
• Leprosy-associated skin lesions (historical use in India and Madagascar)

Mechanism of Action

Primary Mechanisms — Venotonic and Connective Tissue Effects

Collagen synthesis stimulation

• Asiatic acid and madecassic acid stimulate type I and type III collagen synthesis in fibroblasts
• Asiaticoside upregulates procollagen gene expression (COL1A1)
• Enhances tensile strength of connective tissue in venous walls and skin
• This dual action — strengthening venous walls and accelerating wound repair — is the central pharmacological effect

Glycosaminoglycan (GAG) modulation

• TTFCA increases synthesis of mucopolysaccharides (hyaluronic acid, chondroitin sulfate) in the vascular basement membrane and extracellular matrix
• Preserves the structural integrity of the venous endothelial glycocalyx
• Inhibits pathological breakdown of connective tissue ground substance

Microcirculatory improvement

• Reduces capillary permeability by stabilizing the endothelial barrier
• Improves transcutaneous oxygen tension (TcPO2) in areas of venous stasis
• Enhances capillary filtration rate normalization in CVI patients

Secondary Mechanisms

Anti-inflammatory activity

• Asiaticoside inhibits NF-kB activation and reduces TNF-alpha, IL-1beta, and IL-6 production
• Madecassoside has demonstrated anti-inflammatory effects comparable to hydrocortisone in some experimental models
• Reduces excessive inflammatory response in wound healing

Scar modulation

• Modulates collagen remodeling by influencing the ratio of type I to type III collagen
• Inhibits excessive fibroblast proliferation in keloid and hypertrophic scar tissue
• Regulates TGF-beta signaling, which controls fibrosis

Neuroprotective effects (secondary)

• Asiatic acid has demonstrated neuroprotective activity in cell culture and animal models
• Enhances dendritic arborization and neurite outgrowth in hippocampal neurons
• This underlies the traditional Ayurvedic use as a “brain tonic” but human evidence is limited

Clinical Evidence Summary

Volume and Quality of Evidence

• Multiple controlled clinical trials, primarily from Italian research groups (Belcaro, Cesarone, De Sanctis) using TTFCA
• Several trials specifically addressed venous microangiopathy with laser Doppler and transcutaneous oximetry endpoints
• No Cochrane review; no large multicenter RCTs
• WHO Monographs (Volume 1) reviewed the evidence and support CVI and wound-healing indications

Key Clinical Trials

Evidence Assessment

• CVI and venous microangiopathy: Consistent positive results across multiple trials with objective microcirculatory endpoints; the most robust evidence base for this herb
• Wound healing and scarring: Positive signals from controlled trials and extensive preclinical evidence; mechanism well-characterized
• Cognitive effects: Preliminary human studies suggest anxiolytic and cognitive effects, but evidence is insufficient for clinical recommendations
• Overall: Moderate evidence base; stronger than many traditional herbs but lacking the large-scale confirmatory trials that would warrant well-established use status

European vs US/Anglophone Consensus

Safety Profile

Contraindications

• Known hypersensitivity to Centella asiatica or Apiaceae family plants
• Severe hepatic impairment (precautionary due to rare hepatotoxicity reports)
• History of hepatotoxicity with prior Centella use

Drug Interactions

• Hepatotoxic drugs: Potential additive hepatotoxicity; caution with acetaminophen (high-dose), statins, amiodarone, methotrexate, and other hepatotoxic medications. Three case reports of hepatotoxicity (reversible jaundice and elevated liver enzymes) have been associated with Centella preparations
• Sedatives and CNS depressants: Potential additive sedation based on anxiolytic activity observed in preclinical and preliminary human studies; caution with benzodiazepines, barbiturates, and other CNS depressants
• Antidiabetic agents: Theoretical hypoglycemic effect (limited evidence); monitor blood glucose
• Cholesterol-lowering drugs: Theoretical interaction based on preclinical lipid-lowering activity

Side Effects

• Generally well tolerated at recommended oral doses
• Occasional: GI discomfort (nausea, stomach pain), headache
• Uncommon: Drowsiness, dizziness
• Rare: Allergic contact dermatitis (topical application)
• Very rare: Hepatotoxicity — three published case reports of jaundice associated with Centella-containing products (all resolved upon discontinuation)
• Topical: Generally well tolerated; rare contact sensitization

Pregnancy/Lactation

• Not recommended during pregnancy — asiaticoside has shown anti-fertility effects in animal studies (reduced implantation)
• Insufficient safety data for lactation; avoid use
• EMA states: “Use in children and adolescents under 18 years of age is not recommended due to lack of adequate data”

Clinical Dosage

Key point: TTFCA (Total Triterpenic Fraction of Centella asiatica) is the preparation with the strongest clinical evidence. It is standardized to contain defined proportions of asiaticoside, asiatic acid, and madecassic acid. Generic “gotu kola” supplements may not be equivalent.

Sources

• EMA/HMPC Assessment Report on Centella asiatica (L.) Urb., herba
• EMA/HMPC Herbal Monograph on Centella asiatica (L.) Urb., herba
• WHO Monographs on Selected Medicinal Plants, Volume 1: Herbae Centellae
• Brinkhaus B, et al. Centella asiatica in dermatology and venous insufficiency: a systematic review. Phytomedicine. 2000;7(5):427-442
• Pointel JP, et al. Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology. 1987;38(1):46-50
• Belcaro GV, et al. Capillary filtration and ankle edema in patients with venous hypertension treated with TTFCA. Angiology. 1990;41(1):12-18
• Cesarone MR, et al. Evaluation of treatment of diabetic microangiopathy with total triterpenic fraction of Centella asiatica. Angiology. 2001;52(Suppl 2):S49-54
• Incandela L, et al. Treatment of superficial vein thrombosis with orally administered Centella asiatica extract. Angiology. 2001;52(Suppl 2):S61-67
• Natural Medicines Database: Gotu Kola monograph

Connections

• Compare with Horse Chestnut and Red Vine Leaf as alternative venoactive phytomedicines for CVI — horse chestnut has stronger European regulatory recognition
• Compare with Butcher’s Broom for overlapping CVI indications and complementary mechanisms (ruscogenins vs triterpenes)
• Compare with Ginkgo for peripheral microcirculatory effects and cognitive indications
• Notable cross-traditional herb: unlike most European venoactive drugs, gotu kola also has deep roots in Ayurvedic medicine (as medhya rasayana for cognitive and nervous system support)